Disclosed are compounds of formula I, and any salt thereof, and methods for their preparation. Specific examples of compounds of formula I include: [7-(3,5-Difluoro-4-morpholin-4-ylmethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(5-methyl-6-piperazin-1-yl-pyridin-3-yl)-amine, [7-(3,5-Difluoro-4-morpholin-4-ylmethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-[6-(cis-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-amine, 4-[2-(4-Fluoro-phenylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-N-(2-morpholin-4-yl-ethyl)-benzamide, [7-(3,5-Difluoro-4-morpholin-4-ylmethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-[6-(cis-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-amine, and { 7-[4-(4-Ethyl-piperazin-1-ylmethyl)-3-fluoro-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl} -(4-fluoro-3-methyl-phenyl)-amine. Also disclosed are compounds of formula (I) as pharmaceuticals for treating Janus kinase 2 (JAK2 kinase) mediated diseases such as tumor (tumour) disease, leukaemia, polycythemia vera, essential thrombocythemia or myelofibrosis with myeloid metaplasia.
